1. Home
  2. SCYX vs ATCH Comparison

SCYX vs ATCH Comparison

Compare SCYX & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$1.00

Market Cap

41.0M

Sector

Health Care

ML Signal

HOLD

Logo AtlasClear Holdings Inc.

ATCH

AtlasClear Holdings Inc.

HOLD

Current Price

$0.25

Market Cap

34.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
ATCH
Founded
1999
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.0M
34.9M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
SCYX
ATCH
Price
$1.00
$0.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$1.00
AVG Volume (30 Days)
427.0K
1.8M
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
N/A
EPS
N/A
0.06
Revenue
$257,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$608.78
N/A
P/E Ratio
N/A
$3.97
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.14
52 Week High
$1.29
$1.92

Technical Indicators

Market Signals
Indicator
SCYX
ATCH
Relative Strength Index (RSI) 65.62 64.96
Support Level $0.65 $0.25
Resistance Level $1.29 $0.28
Average True Range (ATR) 0.07 0.02
MACD 0.01 0.01
Stochastic Oscillator 97.94 90.96

Price Performance

Historical Comparison
SCYX
ATCH

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About ATCH AtlasClear Holdings Inc.

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

Share on Social Networks: